Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching antidepressants to increase endoxifen exposure during tamoxifen therapy
NL-OMON38029Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of paroxetine, venlafaxine, escitalopram and tamoxifen in breast cancer (2 arms), sponsored by Erasmus MC. Primary endpoint: Effects of antidepressant switch on tamoxifen pharmacokinetics. Started Nov 2011; status: active, not recruiting.
02
Drugs
paroxetinevenlafaxineescitalopramtamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON38029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38029.